Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
CC transcript
Quarterly results
Appointed director
|
|
Viracta Therapeutics, Inc. (VIRX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/08/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/14/2022 |
SC 13G
| Aisling Capital IV, LP reports a 0.8% stake in Viracta Therapeutics, Inc. |
| 02/04/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 03/08/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/04/2021 |
SC 13G
| LYTTON LAURENCE W reports a 8.8% stake in Sunesis Pharmaceuticals, Inc. |
| 08/07/2020 |
SC 13G
| Ayrton Capital LLC reports a 6.6% stake in Sunesis Pharmaceuticals INC |
| 08/03/2020 |
SC 13G
| CVI Investments, Inc. reports a 5.3% stake in Sunesis Pharmaceuticals, Inc. |
| 07/29/2020 |
SC 13G
| SABBY MANAGEMENT, LLC reports a 6.6% stake in Sunesis Pharmaceuticals, Inc. |
| 03/11/2020 |
SC 13G
| Avidity Partners Management LP reports a 4.4% stake in Sunesis Pharmaceuticals, Inc. |
| 03/05/2020 |
SC 13G
| Samsara BioCapital, L.P. reports a 5.3% stake in Sunesis Pharmaceuticals, Inc. |
| 02/14/2020 |
SC 13G
| Nantahala Capital Management, LLC reports a 7.9% stake in SUNESIS PHARMACEUTICALS, INC. |
| 07/22/2019 |
SC 13G
| RTW INVESTMENTS, LLC reports a 6.9% stake in Sunesis Pharmaceuticals, Inc. |
| 07/19/2019 |
SC 13G
| CAXTON CORP reports a 5.3% stake in Sunesis Pharmaceuticals, Inc. |
| 01/28/2019 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/25/2019 |
SC 13G
| JFL Capital Management, LLC reports a 8.2% stake in Sunesis Pharmaceuticals, Inc. |
| 03/05/2018 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/12/2018 |
SC 13G
| EVENTIDE ASSET MANAGEMENT, LLC reports a 6.6% stake in Sunesis Pharmaceuticals, Inc. |
| 11/13/2017 |
SC 13G
| RA CAPITAL MANAGEMENT, LLC reports a 10.4% stake in SUNESIS PHARMACEUTICALS, INC. |
| 11/06/2017 |
SC 13G
| MPM Oncology Impact Management GP LLC reports a 12.5% stake in Sunesis Pharmaceuticals, Inc. |
| 07/05/2017 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals |
| 02/14/2017 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals |
| 01/06/2017 |
SC 13G
| Aisling Capital IV, LP reports a 6.2% stake in Sunesis Pharmaceuticals, Inc. |
| 10/31/2016 |
SC 13G
| Cormorant Asset Management, LLC reports a 5.1% stake in Sunesis Pharmaceuticals, Inc. |
| 02/16/2016 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals |
| 09/26/2012 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals |
| 09/21/2012 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals |
| 02/25/2010 |
SC 13G
| Caxton Advantage Life Sciences Fund, L.P. reports a 6.8% stake in Sunesis Pharmaceuticals Inc |
| 02/16/2010 |
SC 13G
| SUNESIS PHARMACEUTICALS INC reports a |
| 04/14/2009 |
SC 13G
| Form SC 13G -- Statement of acquisition of beneficial ownership by individuals |
| 04/07/2009 |
SC 13G
| VISION CAPITAL ADVISORS, LLC reports a 6.1% stake in Sunesis Pharmaceuticals, Inc. |
|
|